Thereby, we propose the combined of JPX and its downstream gene urokinase-type plasminogen activator (PLAU) inhibitors as a novel therapeutic strategy to target HNSCC and provide new insights into precision oncology. The gene discussed is JPX; the disease is head and neck squamous cell carcinoma.